How personalized medicine can attack the #1 killer in the US

11/12/2013

Tom Callis, PhD

This article, by Transgenomic's Tom Callis, explores how genetic testing can predict a patient's genetic predisposition to cardiovascular drug response and adverse events to help clinicians determine necessary dose adjustments...

“Everybody wants to go to heaven, but nobody wants to die!”: Strategie…

10/12/2013

Virgil Simons

In this article, the founder and president of The Prostate Net, Virgil Simons, presents his ideas on how pharma companies can come up with a strategy in order to achieve...

Success factors in value communication design – Layering Information

10/12/2013

Gijs Hubben

Gijs Hubben presents part three of 'Success factors in value communication design', a set of articles that examines the key success factors in creating customer engagement tools that effectively communicate...

A new frontier for the life sciences industry

09/12/2013

Chris McManus

Accenture's Chris McManus explores the Integrated Business Model within the life science industry.In today's challenging environment, life sciences companies - from established pharmaceutical and medical technology companies to emerging biotech...

UCB invests in UK with cutting-edge robotics

11/12/2013

Markus MacGill

Belgium-based biopharma UCB has selected the UK for the home of a £3.3 million investment in innovative robotics, designed by British experts, to automate antibody discovery.The technology enables a highly...

J&J nestles into five UK ‘excellence’ cities

10/12/2013

Markus MacGill

Johnson & Johnson is continuing to establish a scientific networking approach with the establishment of five new partnerships within UK cities it considers to be academic and entrepreneurial "hotspots".The company...

Takeda’s IBD drug wins FDA backing

10/12/2013

Markus MacGill

Takeda's inflammatory bowel disease drug vedolizumab, a gut-selective, anti-inflammatory monoclonal antibody, has been recommended for US regulatory approval for use in adults with moderately to severely active ulcerative colitis (UC)...

200m US dollars pumped into Indian generics firm

09/12/2013

Markus MacGill

Private investment group KKR, traded on the New York Stock Exchange, has taken a $200m interest in Indian generics firm Gland Pharma. Hyderabad-based Gland - which has collaborated with the...

Is there common ground for engagement be…

The growth of online networks for doctors has been accompanied by recognition from the pharmaceutical industry that these digital meeting grounds can...

Executive Perspectives: Jane Griffiths

In the latest in our series of interviews with senior executives...

Full round table: Oncology shaping the …

Watch the full round table video debate on 'oncology shaping the...

Part four: Oncology shaping the future o…

In the final section of our video round table on personalised...

Redefining Market Access - Effective Val…

Chris Shilling

Phenestra's latest white paper highlights the challenges in market access and reimbursement for every company involved in developing new and innovative drugs.

Today, every pharmaceutical company has the patient...

Doctor networks: The rules of engagement…

Tim Ringrose

As online doctor networks have grown they have also developed their own rules around how members interact, what sort of information they are looking for and how they like to...

Empowering the carer within health and s…

Hannah Gagen

As the UK health and social care systems look to improve patient services in the primary care setting, attention must turn to how carers, an army of around 6.5 million...

Personalised Medicine – the Future of Bl…

Stephen Allport

The personalised medicine approach is rapidly becoming the new norm for pharmaceutical industry drug development and commercialisation, but it demands much more forward-thinking decision-making, as Phenestra outlines in its latest...